ZofranLegal.com reports that many of the more than 230 plaintiffs involved in MDL 2657 allege that their child’s cardiac birth defect was caused by the drug Zofran.
Zofran, an anti-emetic, was first introduced to the market in 1991 after the U.S. Food and Drug Administration approved it for the treatment of nausea and vomiting in patients who have been treated with radiation, chemotherapy, or anesthesia. The manufacturers, GlaxoSmithKline, also informed the medical community and the public that the medication was safe for expectant mothers as a treatment for morning sickness, a condition frequently diagnosed during the first trimester. Many, including the current plaintiffs involved in MDL 2657 and the U.S. Department of Justice, have alleged that the company’s marketing campaign for the use of the drug “off-label” was unlawful.
Parents are now claiming that this advertising, which resulted in millions of pregnant women being prescribed the drug, is what ultimately led to birth defects in their unborn children. Of the various birth defects noted in the complaints, some of the most serious are cardiac defects such as atrial septal defect, ventricular septal defect, transposition of the greater vessels, and tetralogy of fallot.
Each of these defects requires surgical intervention in order to save the life of the child. The patient frequently requires continuous testing and is left with scarring. In a few unfortunate cases, the defect was severe enough that doctors were unable to save the baby.
The parents of these children are seeking compensation from GSK for the cost of necessary medical treatments, physical pain and suffering, and emotional trauma.
The attorneys at Monheit Law wants anyone who believes that their child developed a defect after being exposed to Zofran in the womb, to have the opportunity to explore their legal options. The firm is currently offering free consultations to qualified families. To learn more, contact Michael Monheit at 877-620-8411.
Sponsored by an alliance of attorneys, ZofranLegal.com is a resource for parents, families and birth defect survivors interested in learning more about litigation surrounding the nausea drug Zofran and its link to increased risks of major birth defects.
1368 Barrowdale Road, Rydal, PA 19046
April 30, 2016 – Lawsuit Alleges Invokana Side Effects Can Include Diabetic Ketoacidosis, a Life-Threatening Condition Related to Too Much Acid in the Body
April 29, 2016 – Zofran Lawsuit Update: Plaintiffs Question Why GSK Hasn’t Faced Stiffer Penalties
April 27, 2016 – Arkansas Mother Files Zofran Lawsuit Claiming Multiple Defects Caused By Drug
April 25, 2016 – Zofran Lawsuit Plaintiffs Applaud FDA’s Decision Regarding Folic Acid
April 22, 2016 – MyFoxBoston News Release Discusses Concerning Zofran Birth Defect Lawsuits And Drug Safety
April 22, 2016 – Zofran Lawsuit Plaintiffs Note Results Of Japanese Animal Studies Linking Birth Defects To Drug
April 22, 2016 – A Look Back At America’s First Zofran Lawsuit
April 21, 2016 – Significant Increase In Birth Defect Development Investigated By Washington State Amid Mounting Zofran Lawsuits
April 21, 2016 – Zofran Lawsuit Plaintiffs Make Note Of Canadian Label Differences On Drug Which Warn Of Use During Pregnancy
April 20, 2016 – Zofran Lawsuit Plaintiff Claims Infant’s Cleft Palate, Clubfoot, And Respiratory Distress Caused By Drug Exposure
